Abstract
The fifth most prevalent cancer in the world is gastric cancer, which is aggressive illness with a low 5-year survival rate. Even though stomach cancer is becoming less frequent, patients still have a poor prognosis. Thus, early discovery using relevant screening methods, selection of an acceptable treatment strategy, and good monitoring are critical to reducing gastric cancer mortality. Biomarker identification based on clinical data and extensive genomic analysis might enhance diagnosis, prognosis, recurrence prediction, and therapy response. These biomarkers can also enable more specialized treatment strategies. This study provided an overview of the present state and methods in gastric cancer biomarkers, which may be applied for accurate treatment approach prediction, early diagnosis, and future perspectives.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
